Patent ID: 8273538
Filing Date: 2012-09-25
Classification: G01N

Abstract:
1. A method for determining the risk of neurological manifestations of HIV infection in an HIV-1-infected subject, comprising: (a) obtaining a first blood, serum, or plasma sample from the subject; (b) determining from the first blood, serum, or plasma sample a fraction of CD163+/CD16+ monocytes in a population of peripheral blood mononuclear cells, an HIV-1 viral load, and a CD4+ T cell count; (c) at a different time, obtaining a subsequent blood, serum, or plasma sample from the subject; and (d) determining from the subsequent blood, serum, or plasma sample a fraction of CD163+/CD16+ monocytes in a population of peripheral blood mononuclear cells, an HIV-1 viral load, and a CD4+ T cell count; wherein when the fractions of CD163+/CD16+ monocytes in peripheral blood mononuclear cells and the HIV-1 viral loads in steps (b) and (d) are above a baseline fraction and a baseline HIV-1 viral load in healthy seronegative subjects respectively while the CD4+ T cell counts in steps (b) and (d) are below a baseline count in healthy seronegative subjects, this is indicative of the risk of neurological manifestations of HIV infection in the HIV-1-infected subject.